Study guide
Ototoxic Medications, Pharmacology & Monitoring Protocols
Praxis Audiology 5343
Track your progress as you read
Finished sections get a check mark.
1 Acoustics, Psychoacoustics & Sound Measurement
Physics of Sound, Wave Propagation & Decibel Scales (SPL, HL, SL) Psychoacoustics, Equal Loudness Contours & Frequency Selectivity Speech Acoustics, Formant Structure & Auditory Perception
2 Auditory and Vestibular Anatomy and Physiology
Peripheral Auditory System: Outer, Middle & Inner Ear Transduction Vestibular End Organs, Semicircular Canals & Otolith Mechanics Central Auditory Pathways, Neuroanatomy & Lifespan Structural Maturation Auditory Behavior, Speech-Language Development & Effects of Hearing Loss Across the Lifespan
3 Auditory Pathologies, Genetics & Instrumentation
Outer, Middle, and Inner Ear Pathologies & Genetic Syndromes Nongenetic Systemic Conditions & Infectious Causes of Hearing and Balance Disorders Ototoxic Medications, Pharmacology & Monitoring Protocols Audiometric Instrumentation, Calibration Standards (ANSI S3.6) & Psychometrics
4 Prevention, Lifespan Screening & Hearing Conservation
Universal Newborn Hearing Screening & JCIH Protocols Pediatric and School-Age Hearing Screening Procedures Adult and Geriatric Hearing Screening & Self-Assessment Measures Screening for Speech-Language, Cognitive & Other Conditions and Screening Program Performance Occupational Hearing Conservation, Noise Exposure & OSHA Regulations Hearing Health Education, Fall-Risk Identification & Audiometric and Balance Monitoring
5 Behavioral Pure-Tone Audiometry & Masking
Clinical Preparation: Case History, Otoscopy & Selecting and Modifying Tests Air and Bone Conduction Pure-Tone Testing & Audiogram Interpretation Clinical Masking Principles, Interaural Attenuation & Plateau Method Non-Organic Hearing Loss, Pseudohypacusis & Stenger Testing
6 Speech Audiometry & Pediatric Behavioral Evaluation
Speech Detection & Recognition Thresholds (SDT/SRT) & Word Recognition (WRS) Speech-in-Noise Testing, PB-Max & Retrocochlear Rollover Diagnostics Central Auditory Processing Assessment: Dichotic, Temporal, Spatial & Low-Redundancy Tests Pediatric Behavioral Audiometry: BOA, VRA, and CPA
7 Acoustic Immittance & Middle Ear Diagnostics
Tympanometric Principles, Jerger Classification & Eustachian Tube Function Acoustic Reflex Thresholds, Reflex Arc Pathways & Reflex Decay Analysis Multi-Frequency Immittance, High-Frequency Probe Tones & Infant Protocols
8 Otoacoustic Emissions & Auditory Evoked Potentials
Transient and Distortion Product Otoacoustic Emissions (TEOAE & DPOAE) Auditory Brainstem Response (ABR) Diagnostic Protocols & Wave Analysis ASSR, Electrocochleography (ECochG) & Late Auditory Evoked Potentials
9 Vestibular & Balance Assessment
Videonystagmography (VNG), Oculomotor Tracking & Positional Nystagmus Bithermal Caloric Testing, Jongkees Formula & Rotational Chair Evaluation Video Head Impulse Test (vHIT), VEMP (cVEMP/oVEMP) & Dynamic Posturography (CDP) Integrating Assessment Results, Differential Diagnosis & Reporting
10 Hearing Aid Selection, Features & Prescriptive Fitting
Treatment Planning, Goal Setting, Progress Monitoring & Intervention Documentation Hearing Aid Components, Acoustic Transducers & Digital Signal Processing Prescriptive Fitting Targets (NAL-NL2 vs. DSL m[i/o]) & Dynamic Range CROS, BiCROS & Severe-to-Profound Fitting Strategies
11 Amplification Verification, Validation & Troubleshooting
Probe-Microphone Real-Ear Verification (REUR, REAR, REIG & RECD) ANSI S3.22 Electroacoustic Analysis & Quality Control Standards Clinical Validation Inventories (COSI, APHAB, SSQ) & Device Troubleshooting
12 Implantable Devices & Hearing Assistive Technology
Bone-Conduction Systems (BAHS) & Active Middle Ear Implants Cochlear Implants: Candidacy, Telemetry, MAPping Parameters & ABI Systems Hearing Assistive Technology, FM/DM Classroom Systems & Telecoils
13 Aural Rehabilitation, Tinnitus & Vestibular Management
Adult and Pediatric Aural Rehabilitation & Communication Strategies Tinnitus Management, Sound Therapy & Decreased Sound Tolerance Protocols Canalith Repositioning Maneuvers for BPPV & Vestibular Rehabilitation Therapy (VRT)
14 Ethics, Scope of Practice & Interprofessional Collaboration
ASHA and AAA Codes of Ethics, Ethical Decision-Making & Conflict of Interest Clinical Scope of Practice, CCC-A Credentialing, Licensure & Clinical Supervision Service Delivery Models, Practice Management, Risk Management & Advocacy Patient/Family Counseling & Interprofessional Practice in Education and Healthcare
15 Regulatory Compliance, Safety & Evidence-Based Practice
Federal Regulations (HIPAA, FERPA, ADA, OSHA), Billing Compliance & Infection Control Evidence-Based Practice, Research Methodology & Teleaudiology Service Delivery
Ototoxic Medications, Pharmacology & Monitoring Protocols
Key Takeaways Explain This Topic AI
Aminoglycoside antibiotics destroy outer hair cells from base to apex via iron-chelated reactive oxygen species (ROS); gentamicin and streptomycin are predominantly vestibulotoxic, whereas amikacin, neomycin, and kanamycin are predominantly cochleotoxic.
Platinum chemotherapeutics (cisplatin and carboplatin) cross-link DNA and generate reactive oxygen species, producing irreversible, bilateral high-frequency sensorineural hearing loss that disproportionately damages pediatric language development.
Loop diuretics (furosemide, bumetanide) disrupt the NKCC1 cotransporter in the stria vascularis, causing temporary hearing loss alone, but triggering catastrophic, permanent cochlear necrosis when administered synergistically with aminoglycosides.
The Sensitive Range for Ototoxicity (SRO) defines an individualized one-octave frequency band consisting of the highest frequency with a threshold at or below 100 dB SPL down one octave, enabling rapid targeted surveillance before speech frequencies are impaired.
The ASHA criteria for a significant ototoxic threshold shift mandate confirmation by retest within 24 hours of: a 20 dB decrease at any single frequency, a 10 dB decrease at two consecutive frequencies, or loss of response at three consecutive frequencies where responses previously existed.
Last updated: October 2026
Ototoxic Medications, Pharmacology & Monitoring Protocols
Pharmacological ototoxicity refers to drug- or chemical-induced cellular damage to the inner ear's sensory hair cells, stria vascularis, or vestibular end organs. Because ototoxic threshold shifts begin at the basal turn of the cochlea, systematic monitoring allows audiological and medical intervention before communicative speech frequencies ( 0.5 − 4 kHz 0.5-4\,\text{kHz} 0.5 − 4 kHz ) are permanently damaged.
1. Major Classes of Ototoxic Pharmaceuticals
Understanding the cellular pharmacodynamics, target structures, and clinical presentation of each ototoxic drug class is vital for clinical diagnosis, patient safety, and medical collaboration.
Comprehensive Ototoxic Drug Comparison Matrix
Pharmacological Class Representative Agents Primary Cellular Targets & Mechanisms Clinical Manifestation Reversibility Profile Critical Risk Factors & Interactions
Aminoglycoside Antibiotics Gentamicin, Tobramycin, Amikacin, Streptomycin, Neomycin Iron-chelate ROS generation; outer hair cell apoptosis; basal to apical gradient High-frequency SNHL, oscillopsia, dynamic ataxia, vestibular hypofunction Irreversible permanent loss Renal impairment; prolonged therapy > 14 >14 > 14 days; synergy with loop diuretics; m.1555A>G mutation
Platinum Chemotherapy Cisplatin, Carboplatin DNA cross-linking; ROS accumulation; OHC apoptosis; stria vascularis atrophy Bilateral, symmetrical high-frequency SNHL ( 9 − 20 kHz 9-20\,\text{kHz} 9 − 20 kHz first); tinnitus Irreversible permanent loss High cumulative dose; bolus infusion; prior cranial radiation; age < 5 <5 < 5 years
Loop Diuretics Furosemide (Lasix), Bumetanide, Ethacrynic Acid Inhibition of N a + / K + / 2 C l − Na^+/K^+/2Cl^- N a + / K + /2 C l − (NKCC1) cotransporter in stria vascularis; drop in EP Acute flat or high-frequency SNHL; tinnitus; aural fullness Reversible within 24–72h if monotherapy Rapid IV bolus; renal failure; lethal permanent synergy when combined with aminoglycosides
Salicylates & NSAIDs Aspirin (acetylsalicylic acid), High-dose NSAIDs Competitive inhibition of prestin motor protein; reduced OHC electromotility Mild-to-moderate flat/sloping SNHL; loud high-pitched tinnitus Reversible completely within 24–72h of cessation Supratherapeutic serum salicylate levels ( > 30 mg/dL >30\,\text{mg/dL} > 30 mg/dL ); chronic high-dose therapy
Antimalarials Quinine, Chloroquine, Hydroxychloroquine OHC stereocilia damage; altered cochlear microcirculation; cinchonism High-frequency SNHL; tinnitus; vertigo; visual disturbances Typically reversible; permanent in toxic overdose Prolonged systemic autoimmune regimens; renal/hepatic dysfunction
Industrial Solvents & Chemicals Toluene, Styrene, Xylene, Carbon Monoxide Lipid membrane dissolution; OHC loss; central auditory processing degradation High-frequency SNHL; speech-in-noise deficit; central auditory dysfunction Irreversible permanent loss Combined exposure with occupational noise ( ≥ 85 dBA \ge 85\,\text{dBA} ≥ 85 dBA produces potent synergy)
- In-Depth Pharmacodynamics by Drug Class
- 1. Aminoglycoside Antibiotics
Cellular Mechanism : Aminoglycosides enter outer hair cells through mechanosensitive transduction (MET) channels at the stereocilia tips. Once inside the hair cell cytoplasm, clearance is exceptionally slow: aminoglycosides can persist in cochlear and vestibular tissues for weeks to months, in contrast to a serum half-life of only a few hours. The drug molecules bind with intracellular transition metals (primarily iron, F e 2 + Fe^{2+} F e 2 + ), forming an iron-drug complex that catalyzes the formation of reactive oxygen species (ROS) , including hydroxyl radicals, superoxide anions, and hydrogen peroxide. These free radicals trigger lipid peroxidation, mitochondrial cytochrome c release, and caspase-mediated apoptosis of outer hair cells.
Tonotopic Progression : Destruction proceeds systematically from the high-frequency basal turn toward the low-frequency apical turn , with outer hair cells destroyed prior to inner hair cells.
Cochleotoxicity vs. Vestibulotoxicity :
Predominantly Vestibulotoxic : Gentamicin and streptomycin . These agents preferentially target Type I sensory hair cells within the cristae ampullares of the semicircular canals. Clinical toxicity manifests not with sudden deafness, but with oscillopsia (the illusory bouncing or bobbing of the visual field during head movement, termed Dandy's sign ), dynamic unsteadiness, ataxia in darkness, and bilateral vestibular hypofunction.
Predominantly Cochleotoxic : Amikacin , neomycin , and kanamycin . These agents preferentially destroy cochlear outer hair cells, generating rapid, irreversible bilateral high-frequency sensorineural hearing loss and tinnitus.
Equipotent Toxicity : Tobramycin damages both cochlear and vestibular end organs with equal frequency and severity.
Mitochondrial Genetic Susceptibility : The mitochondrial m.1555A>G mutation in the 12S rRNA gene modifies human mitochondrial ribosomes so that they structurally resemble the bacterial 16S rRNA targeted by aminoglycosides. Individuals harboring this maternally inherited mutation are prone to developing profound, permanent, bilateral deafness following even a single standard therapeutic dose of an aminoglycoside.
2. Platinum-Based Chemotherapy
Cellular Mechanism : Cisplatin and carboplatin are widely prescribed antineoplastic agents for solid tumors (pediatric neuroblastoma, osteosarcoma, medulloblastoma; adult head/neck, lung, ovarian, and testicular cancers). Cisplatin binds covalently to nuclear and mitochondrial DNA, forming platinum-DNA adducts and intrastrand cross-links that halt transcription and trigger programmed cell death. In the inner ear, cisplatin accumulates in the stria vascularis , outer hair cells , and spiral ganglion cells , depleting antioxidant enzymes (superoxide dismutase, glutathione peroxidase) and provoking massive ROS cascades.
Clinical Presentation : Cisplatin ototoxicity is bilateral, symmetrical, permanent, and irreversible . It typically manifests initially as an asymptomatic threshold shift in the extended high frequencies ( 9 , 000 to 20 , 000 Hz 9,000\text{ to }20,000\,\text{Hz} 9 , 000 to 20 , 000 Hz ) accompanied by persistent, high-pitched ringing tinnitus. As cumulative dosage increases, the threshold elevation spreads into the conventional speech frequencies ( 4 kHz 4\,\text{kHz} 4 kHz , 2 kHz 2\,\text{kHz} 2 kHz , and 1 kHz 1\,\text{kHz} 1 kHz ).
Cisplatin vs. Carboplatin : Cisplatin is significantly more ototoxic, causing significant hearing loss in 40 % to 80 % 40\%\text{ to }80\% 40% to 80% of adult patients. Carboplatin is generally less ototoxic at standard dosages, but becomes markedly ototoxic during high-dose marrow-ablation conditioning or when administered after prior cisplatin therapy.
Pediatric Vulnerability : Infants and children under 5 years of age are exceptionally vulnerable. Even mild-to-moderate high-frequency hearing loss can disrupt speech-language acquisition, phonological development, and academic success. Pediatric ototoxicity is graded using standardized frameworks such as the Brock scale (Grade 0: < 40 dB <40\,\text{dB} < 40 dB at all frequencies; Grade 1: ≥ 40 dB \ge 40\,\text{dB} ≥ 40 dB at 8 kHz 8\,\text{kHz} 8 kHz ; Grade 2: ≥ 40 dB \ge 40\,\text{dB} ≥ 40 dB at 4 kHz 4\,\text{kHz} 4 kHz ; Grade 3: ≥ 40 dB \ge 40\,\text{dB} ≥ 40 dB at 2 kHz 2\,\text{kHz} 2 kHz ; Grade 4: ≥ 40 dB \ge 40\,\text{dB} ≥ 40 dB at 1 kHz 1\,\text{kHz} 1 kHz ) or the Chang scale .
Otoprotective Agents : Sodium thiosulfate (STS) is FDA-approved as an otoprotective agent administered intravenously exactly 6 hours after cisplatin infusion in pediatric patients with localized, non-metastatic solid tumors, acting as a free-radical scavenger and covalent platinum-chelating agent.
3. Loop Diuretics
Mechanism : Furosemide, bumetanide, and ethacrynic acid are powerful diuretics that act on the loop of Henle in the kidney and simultaneously inhibit the N a + / K + / 2 C l − Na^+/K^+/2Cl^- N a + / K + /2 C l − cotransporter (NKCC1) located in the marginal cells of the cochlear stria vascularis .
Physiological Consequence : Inactivation of the NKCC1 cotransporter abolishes the active secretion of potassium ( K + K^+ K + ) into the scala media, causing an immediate collapse of the endocochlear potential from its normal resting level of + 80 mV +80\,\text{mV} + 80 mV down to near 0 mV 0\,\text{mV} 0 mV . This induces profound strial intracellular edema and eliminates the electrical driving voltage that powers hair cell transduction.
Reversibility : Loop diuretic ototoxicity alone is typically transient and reversible , recovering within 24 to 72 hours following drug clearance as strial cellular edema resolves.
Synergistic Ototoxicity Trap : When a loop diuretic is administered concurrently with or shortly after an aminoglycoside antibiotic, a catastrophic synergistic ototoxicity occurs. The diuretic-induced strial edema alters permeability barriers, allowing massive, unchecked concentrations of aminoglycosides to flood the endolymph and penetrate hair cells, transforming an otherwise reversible insult into immediate, permanent, severe-to-profound cochlear necrosis.
2. ASHA and AAA Ototoxicity Monitoring Protocols
Systematic ototoxicity monitoring protocols established by the American Speech-Language-Hearing Association (ASHA) and the American Academy of Audiology (AAA) are designed to detect subclinical hearing loss before it impairs functional speech communication.
Clinical Objectives of Monitoring
Identify cochlear damage at its earliest onset in the ultra-high frequencies ( > 8 kHz >8\,\text{kHz} > 8 kHz ).
Alert the medical oncology or infectious disease team, enabling them to evaluate modifying dosage, dividing infusion schedules, substituting non-ototoxic medications, or adding otoprotective agents.
Initiate timely rehabilitative counseling, assistive listening devices, or personal amplification before a communicative handicap isolates the patient.
Evaluation Timing and Protocol Flow
Baseline Assessment :
Timing : Ideally completed before the first dose . If that is not possible, AAA (2009) guidance is within 24 hours of the first platinum chemotherapy dose or within 72 hours of starting aminoglycoside therapy.
Battery : Otoscopy, 226 Hz tympanometry (to rule out middle ear effusion or negative pressure that would invalidate threshold comparison), comprehensive pure-tone audiometry ( 0.25 − 8 kHz 0.25-8\,\text{kHz} 0.25 − 8 kHz ), extended high-frequency audiometry ( 9 − 20 kHz 9-20\,\text{kHz} 9 − 20 kHz ), distortion product otoacoustic emissions (DPOAEs), and baseline speech recognition.
Serial Monitoring Evaluations :
Performed immediately prior to each subsequent chemotherapy infusion cycle, or once-to-twice weekly for hospitalized patients receiving intravenous aminoglycosides.
Focuses on the Sensitive Range for Ototoxicity (SRO) to minimize testing time in fatigued or critically ill patients.
Post-Treatment Follow-up :
Conducted at 1 month, 3 months, 6 months, and 12 months following completion of medical therapy. Post-treatment surveillance is critical because cisplatin can remain active in the cochlea for months, causing delayed, progressive high-frequency sensorineural decline long after infusions have ceased.
The Sensitive Range for Ototoxicity (SRO)
Definition : The SRO is an individualized, narrow frequency window consisting of the highest frequency with a threshold ≤ 100 dB SPL \le 100\,\text{dB}\,\text{SPL} ≤ 100 dB SPL down one octave , evaluated at 1 / 6 -octave 1/6\text{-octave} 1/6 -octave intervals (typically comprising 6 to 7 specific frequencies).
Clinical Utility : Concentrates monitoring on the specific cochlear region most vulnerable to initial ototoxic damage in that individual patient. This shortens pure-tone threshold testing time to 5 to 7 minutes per ear, preventing diagnostic fatigue in critically ill, nauseous, or immunocompromised patients.
- Specialized Diagnostic Modalities
- Extended High-Frequency (EHF / UHF) Audiometry
Evaluates pure-tone air conduction thresholds from 9,000 Hz to 20,000 Hz using circumaural earphones (e.g., Sennheiser HDA 200 or HDA 300) calibrated with dedicated Reference Equivalent Threshold Sound Pressure Levels (RETSPLs).
Because hair cell damage begins at the extreme basal turn of the cochlea, extended high-frequency testing can detect ototoxic threshold shifts days, weeks, or months before changes are visible on a conventional ( 0.25 − 8 kHz 0.25-8\,\text{kHz} 0.25 − 8 kHz ) audiogram.
Distortion Product Otoacoustic Emissions (DPOAE)
Provides an objective, frequency-specific, non-invasive assessment of outer hair cell function without requiring behavioral participation.
A progressive reduction in DPOAE amplitude of ≥ 4 to 6 dB \ge 4\text{ to }6\,\text{dB} ≥ 4 to 6 dB across multiple adjacent f 2 f_2 f 2 frequencies serves as an early physiological warning sign of outer hair cell damage preceding behavioral pure-tone threshold shifts.
Essential for monitoring non-verbal infants, pediatric oncology patients, uncooperative patients, or comatose intensive care unit (ICU) patients.
Clinical Criteria for a Significant Ototoxic Threshold Shift
According to ASHA Guidelines (1994) , a significant ototoxic threshold shift is identified when any of the following criteria are met relative to the baseline audiogram, and confirmed by retest within 24 hours :
- ≥ 20 dB \ge 20\,\text{dB} ≥ 20 dB decrease in pure-tone threshold at any single test frequency ; OR
- ≥ 10 dB \ge 10\,\text{dB} ≥ 10 dB decrease in pure-tone thresholds at two consecutive test frequencies ; OR
Loss of response at three consecutive test frequencies where behavioral responses previously existed at the maximum audiometric output limits.
Important Clinical Rule : A suspected threshold shift must always be confirmed on retest within 24 hours to eliminate momentary patient inattention, fatigue, transient Eustachian tube dysfunction, or ambient test room noise artifacts before notifying the physician.